Intellia Therapeutics, Inc (NTLA) — Analysis Summary
Intellia Therapeutics, Inc (NTLA) has a market cap of $1.97B with year-over-year revenue growth of +16.9%. Net margin stands at -609.9%. The stock trades at a P/E ratio of -5.0.
Key Takeaways
- Revenue changed +16.9% year-over-year
- Net margin of -609.9%
- P/E ratio of -5.0
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, NTLA posted revenue growth of +16.9% and trades at a P/E of -5.0.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.